OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
State on share capital and voting rights (FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.